Neurologic complications (NCs) may be a significant source of morbidity and mortality after hematopoietic cell transplantation (HCT). We performed a retrospective study of 263 consecutive patients undergoing allogeneic HCT for hematological malignancies to determine the incidence, risk factors and clinical impact of NCs in the first 5 years after HCT. We determined the incidence of central nervous system (CNS) infection, intracranial hemorrhage, ischemic stroke, metabolic encephalopathy, posterior reversal encephalopathy syndrome, seizure and peripheral neuropathy. In all, 50 patients experienced 63 NCs-37 early (⩽ day +100), 21 late (day +101 to 2 years) and 5 very late (2 to 5 years). The 1-and 5-year cumulative incidences of all NCs were 15.6% and 19.2%, respectively, and of CNS complication (CNSC; all of the above complications except peripheral neuropathy) were 12.2 and 14.5%. Risk factors for CNSC were age (hazard ratio (HR) = 1.06 per year, P = 0.0034), development of acute GvHD grade III-IV (HR = 2.78, P = 0.041), transfusion-dependent thrombocytopenia (HR = 3.07, P = 0.025) and delayed platelet engraftment (490th centile; HR = 2.77, P = 0.043). CNSCs negatively impacted progression-free survival (HR = 2.29, P = 0.0001), overall survival (HR = 2.63, Po0.0001) and nonrelapse mortality (HR = 8.51, Po0.0001). NCs after HCT are associated with poor outcomes, and usually occur early after HCT.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for patients with hematological malignancies and genetic disorders. Despite advances in supportive care, HLA typing and alternative donor source protocols over the past decades, HCT is still complicated by significant toxicity and transplant-related mortality. 1 Neurologic complications (NCs) are a significant cause of morbidity related to HCT. [2] [3] [4] [5] The etiologies of NCs include drug toxicities (for example, due to calcineurin inhibitors (CNIs) [6] [7] [8] [9] ), infections, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] hemorrhage, [20] [21] [22] ischemia, 21 metabolic effects, posterior reversal encephalopathy syndrome (PRES), [23] [24] [25] [26] [27] [28] toxicity due to cryopreserved hematopoietic cell infusion [29] [30] [31] [32] [33] and disease infiltration. Both the central and peripheral nervous systems can be affected; clinical syndromes include seizures, encephalopathy, focal neurologic deficits and peripheral neuropathies. The severity of these complications ranges from mild to life threatening.
Several studies have sought to define the incidence and characteristics of NCs associated with HCT, with estimates of incidence varying considerably, from~8 to 65% depending on the study design, types of NCs included, patient population and transplantation setting. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] Autopsy studies have uncovered neuropathological findings in as high as 90% of patients who have died following HCT. [49] [50] [51] Many of these studies have found unfavorable survival among patients who develop central nervous system (CNS) complications (CNSCs). 37, [41] [42] [43] [44] However, many of these studies are over 10 years old and do not have long-term follow-up.
Here we report the incidence and long-term outcomes of NCs for patients undergoing allogeneic HCT for hematological malignancies at a single academic center over a 10-year period. Our study provides 5-year follow-up of a large cohort of allogeneic HCT patients, including recipients of alternative donor grafts.
PATIENTS AND METHODS Patients
We performed a retrospective chart review of consecutive patients undergoing HCT for hematological malignancies (leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome and myeloproliferative neoplasms) at the Massachusetts General Hospital between January 2000 and December 2010. We excluded patients undergoing combined kidney and bone marrow transplantation, and those that had received a prior allogeneic HCT. Patients were followed for 5 years after transplant or until death. This study was approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board. Abbreviations: ATG = anti-thymocyte globulin; CNS = central nervous system; CSA = cyclosporine A; HCT = hematopoietic cell transplantation; HL = Hodgkin lymphoma; MAC = myeloablative conditioning (either high-dose TBI or high-dose busulfan in combination with cyclophosphamide); MDS = myelodysplastic syndrome; MM = multiple myeloma; MMF = mycophenolate mofetil; MMUD = mismatched unrelated donor; MPN = myeloproliferative neoplasm; MRD = matched related donor; MTX = methotrexate; MUD = matched unrelated donor; NHL = non-Hodgkin lymphoma; RIC = reduced-intensity conditioning (most commonly fludarabine and busulfan); R/R = relapsed/refractory; SIR = sirolimus; TAC = tacrolimus; UCB = umbilical cord blood donor. P-values were calculated using the χ 2 -test.
determine the effect of CNSC on progression-free survival (PFS), overall survival (OS) and non-relapse mortality (NRM). Only CNSCs were included in these analyses as they were considered more likely to affect NRM, PFS and OS than peripheral neuropathy. The incidence of NCs was determined by review of medical records, including pathology, imaging and notes from neurology consults, where available. We recorded seven types of NCs: CNS infection; intracranial hemorrhage; ischemic stroke; metabolic encephalopathy; PRES; seizure; and peripheral neuropathy. The first six (excluding peripheral neuropathy) were defined as CNSC. NCs that occurred in patients that had relapsed or progressed (including those with a CNS relapse) were recorded but not included in any of the risk factor or survival models described below. CNS infections were either proven based on culture or PCR of cerebrospinal fluid, or considered probable based on imaging and neurology and/or infectious diseases consult opinion. All cases of ischemic stroke and CNS hemorrhage were confirmed by imaging. Metabolic encephalopathy was defined as documented changes in mental state attributable to renal failure, liver failure, respiratory failure, electrolyte imbalance, drug toxicity or sepsis. PRES was defined by magnetic resonance imaging, 58 as reported by a radiologist. Patients with transient changes in mental status where PRES was suspected but not confirmed by imaging were not included. CNS progression of disease was confirmed by imaging or analysis of cerebrospinal fluid. Seizure and peripheral neuropathy were clinical diagnoses. Minor neurologic symptoms such as headache or tremor were excluded unless an underlying cause from the above list was found by imaging or other investigation. Cases of herpes zoster were excluded. We classified neurologic events as early (day − 7 to day +100), late (day +101 to 2 years) or very late (2 to 5 years) as measured from day 0 of HCT.
Statistical methods
PFS was defined as the time from transplantation to relapse, disease progression or death from any cause. OS was defined as the time from transplantation to death from any cause. NRM was defined as death not caused by disease relapse or progression. PFS and OS were calculated using the Kaplan-Meier method. Cumulative incidences of NCs, CNSC, relapse/progression, NRM and aGvHD and chronic GvHD were calculated using the method of competing risks. [59] [60] [61] [62] Relapse/progression and death were considered competing risks to NCs and CNSC, and GvHD. Relapse/ progression was a competing risk to NRM. Censorship was at the last date of follow-up for patients that did not experience an event.
For PFS and OS, regression was using a Cox proportional hazards model. For CNSC and NRM we performed regression on the cause-specific hazard (with the competing event treated as a censoring event) using a Cox proportional hazards model. Only the first CNSC was included in these analyses. Hazard ratios (HRs) are reported with 95% confidence intervals. Explanatory covariates considered were as follows: age; sex; pre-existing CNS condition; primary diagnosis; prior autologous HCT; donor source; conditioning regimen; TBI; ATG; and GvHD prophylaxis. aGvHD and chronic GvHD, neutropenia, transfusion-dependent thrombocytopenia and CNSC were all considered time-dependent covariates when evaluated in the models. 63 Patients were defined as having neutropenia before neutrophil engraftment, and transfusion-dependent thrombocytopenia before platelet engraftment.
To evaluate the effect of early vs late neutrophil or platelet engraftment on CNSC, and of early vs late CNSC on PFS, OS and NRM, we performed landmark analyses. Only patients who had not experienced the outcome of interest by the landmark time were included in the corresponding analysis. Patients were grouped according to whether they had engrafted or experienced CNSC event by the landmark time. The HR for this covariate was calculated using a univariate Cox proportional hazards model. The landmark times were chosen to correspond to the median and 90th centile of engraftment times for neutrophils and platelets, respectively. The landmark time for CNSC was chosen to be 30 days to correspond to the approximate duration of the initial transplant admission, and survival and cumulative incidence curves were calculated for patients who had or had not experienced a CNSC event by this time.
RESULTS

Patient characteristics
Patient and transplant-related characteristics are summarized in Table 1 . There were 263 patients (median age 54 years, range 18-76 years) who underwent allogeneic HCT during this period. The most common underlying diseases were acute myeloid leukemia, n = 91 (35%); non-Hodgkin lymphoma, n = 64 (24%); and myelodysplastic syndrome, n = 41 (16%). Conditioning was myeloablative, n = 86 (33%); or reduced-intensity, n = 177 patients (67%). Donor sources were matched related donor, n = 153 (58%); HLA 8/8 allele level matched unrelated donor, n = 52 (20%); haploidentical, n = 35 (13%); umbilical cord blood, n = 20 (8%); and HLA 7/8 allele level mismatched unrelated donor, n = 3 (1%). Figure 1b ).
The types of NCs were as follows: CNS infection, n = 3 (bacterial meningitis n = 1, viral encephalitis n = 1 and retinal toxoplasmosis n = 1); intracranial hemorrhage, n = 9 (subdural hematoma n = 4, subarachnoid hemorrhage n = 2 and intraparenchymal hemorrhage n = 3); ischemic stroke, n = 9; metabolic encephalopathy, n = 14 (attributed to one or more of the following: renal failure, n = 3; liver failure, n = 3; respiratory failure, n = 2; sepsis, n = 2; CNI toxicity, n = 3; intra-thecal methotrexate toxicity, n = 1; narcotic use, n = 1; benzodiazepine withdrawal, n = 1; and multi-organ dysfunction, n = 4); seizure, n = 9; PRES, n = 5; and peripheral neuropathy, n = 14 ( Figure 1a ). The majority of these events, 37 of 63 (60%) occurred in the early post-transplant period, up to day +100. There were 31 CNSCs and 6 peripheral neuropathies during this period. Notably, all cases of PRES, n = 5, occurred in the early post-transplant period. A total of 3 of the 5 patients who developed PRES were receiving a CNI; the other 2 were receiving sirolimus and mycophenolate mofetil. A further 21 NCs (33%) occurred during the late post-transplant period (day +101 to 2 years)-15 CNSCs and 6 peripheral neuropathies. NCs were rare in the very late post-transplant period (2 to 5 years), with only 5 further events (8%)-3 CNSCs and 2 peripheral neuropathies.
NCs in patients with relapsed or progressive disease A total of 140 of 263 patients relapsed or progressed over the 5-year follow-up period. The 1-and 5-year cumulative incidences of relapse or progression were 39.6% and 53.6%, respectively. The incidence of NCs in patients who had relapsed or progressed was similar to those who had not-27 of those patients (19% of patients who relapsed/progressed) experienced 37 neurologic events as follows: CNS infection, n = 3; intracranial hemorrhage, n = 7; ischemic stroke, n = 5; metabolic encephalopathy, n = 4; PRES, n = 1; seizure, n = 4; CNS disease, n = 10 (including 4 patients who experienced CNS relapse as their first neurologic event post transplant); and peripheral neuropathy, n = 3. Many of these events were related to relapsed or progressive disease or subsequent treatments received and are therefore not directly attributable to the transplant. These events were therefore excluded from subsequent analyses.
Risk factors for CNSC To determine risk factors for CNSCs without prior relapse or progression, we performed a multivariate analysis. Significant risk factors for CNSCs were older age (HR = 1.06 per year, P = 0.0034), prior development of grade III-IV aGvHD (HR = 2.78, P = 0.041) and transfusion-dependent thrombocytopenia (HR = 3.07, P = 0.025; Table 3 ). Transfusion-dependent thrombocytopenia is a timedependent covariate that compares patients that have not engrafted platelets with those that have at any point in timepatients that had not engrafted were at increased risk of CNSC.
Engraftment
In all, 14 patients experienced 21 CNSCs while thrombocytopenic, before platelet engraftment, as follows: CNS infection, n = 1; CNS hemorrhage, n = 4; ischemic stroke, n = 2; metabolic encephalopathy, n = 5; seizure, n = 5; and PRES, n = 4. Neutropenia was not a risk factor for CNSC. As transfusion-dependent thrombocytopenia was found to be a risk factor in the multivariate model as a timedependent covariate, we hypothesized that patients that engrafted late would be at increased risk of CNSC. We therefore performed landmark analyses to compare patients that had engrafted by a fixed time point to those that had not (Table 3) . Platelet engraftment 490th centile of engraftment times (delayed platelet engraftment) was found to be a risk factor for CNSC (HR = 2.77, P = 0.043; Table 3 ).
GvHD
The 100-day cumulative incidence of aGvHD grades III-IV was 16.7%. A total of 55 patients developed aGvHD grades III-IV, and 10 of these patients subsequently experienced a CNSC as follows: CNS hemorrhage, n = 3; ischemic stroke, n = 1; metabolic encephalopathy, n = 5; and seizure, n = 1. The 5-year cumulative incidence of chronic GvHD was 32.0%, and was not a risk factor for CNSC.
Impact of CNSC on survival and NRM
In all, 165 out of 263 patients (63%) died within the 5-year followup period. The major cause of death was progressive disease, n = 118 (72% of patients who died), followed by infection, n = 17 (10%); GvHD, n = 13 (8%); organ toxicity, n = 3 (2%); and second malignancy, n = 3 (2%; post-transplant lymphoproliferative disorder, n = 2 and small-cell carcinoma of unknown primary, n = 1); other, n = 4 (intracranial hemorrhage, n = 2; cardiac arrest, n = 1;
and liver cirrhosis, n = 1); and unknown, n = 7. For the entire cohort, 1-and 5-year PFS was 47.5% and 28.8%, respectively; OS was 63.1% and 36.7%, respectively; and NRM was 12.6% and 17.2%, respectively. Among the 38 patients who developed CNSCs, 9 patients (24%) subsequently relapsed or progressed and 27 patients (71%) died, including 7 of the relapsed/progressed patients. Causes of death were progressive disease (which occurred after the CNSC), n = 7 (18%); infection, n = 6 (16%); GvHD, n = 6 (16%); organ toxicity, n = 1 (3%); second malignancy, n = 1 (3%; small-cell carcinoma of unknown primary, n = 1); and other, n = 3 (8%; intracranial hemorrhage, n = 2 and cardiac arrest, n = 1), and unknown n = 3 (8%). The 2 cases of intracranial hemorrhage were the only deaths directly attributable to CNSC.
CNSC was associated with reduced OS and PFS, and increased NRM (Figure 2 ). There was a significant difference in all three outcomes-from the landmark analysis time of 30 days-between patients in the two groups. Median PFS was 5.1 months with CNSC, compared to 11.1 months without (P = 0.03). Median OS was 5.1 months with CNSC, compared to 27.2 months without (P = 0.001)
To confirm the effect of CNSC on OS, PFS and NRM, we performed multivariate analyses to identify risk factors (Table 4) . Accounting for other covariates, CNSC adversely impacted PFS (HR = 2.29, P = 0.0001), OS (HR = 2.63, P o0.0001) and NRM (HR = 8.51, P o 0.0001).
DISCUSSION
NCs remain an important adverse event associated with allogeneic HCT, however their reported incidence and severity vary widely in the literature. Our cumulative incidence of CNSC of 12.2% at 1 year and 14.5% at 5 years is lower than the majority of prior reports. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] This finding is consistent with the overall trend of reduced morbidity and mortality associated with HCT over time. 64 Despite a relatively low overall incidence of NCs we still found that development of a CNSC portends a poor prognosis and was associated with decreased PFS and OS, and increased NRM, consistent with previous studies. 37, [41] [42] [43] [44] Our long follow-up period of 5 years allowed us to analyze the temporal profile of NCs after transplant and account for late complications that may not have been detected in prior studies. Consistent with previous studies, 4, 43, 44, 64 we found a decreasing incidence of NC over time from transplant, with the majority of events occurring in the early post-transplant period (up to day +100).
The most common NC during all periods was metabolic encephalopathy, which occurred in 14 patients (5.3%). Metabolic encephalopathy was frequently multifactorial, attributed to a combination of multi-organ dysfunction, sepsis and drug toxicity. Treatment was directed at the underlying cause. Cerebrovascular accident (CVA) secondary to ischemia or hemorrhage is a particularly devastating and potentially fatal neurologic event. Previously, Coplin et al. 21 found that 36 of 1245 (2.9%) bone marrow transplant (autologous and allogeneic) patients suffered a CVA over a 3-year period, of whom 25 (2.0%) died of such. The etiology was infectious (mostly Aspergillus spp) in one-third of cases. In our series, only 3 patients suffered hemorrhagic CVA (intraparenchymal hemorrhage) and 9 patients suffered ischemic CVA over the 5-year follow-up, for a combined incidence of 12 of 263 patients (4.6%). However, only 2 patients (0.7%) died of CVA, both hemorrhagic events. There were no fatal ischemic CVAs and no cases of CNS infection (in particular Aspergillus spp) causing CVA. Our overall incidence of CNS infection was low, with only 3 cases (1.1%)-1 each of bacterial meningitis, viral encephalitis and toxoplasmosis.
Several studies have sought to identify risk factors for NC in HCT patients. Siegal et al. 43 identified female sex and TBI as independent risk factors for CNSCs in the first 100 days post transplant. They reported a 1-year incidence of CNSC of 23%, compared with 12.2% in our study. Their 1-year incidence of PRES was also significantly higher, 7% compared with 1.9% in our study. Notably, we used significantly less TBI (only 10% of our patients) and conditioning intensity was myeloablative in only 33% of our cases compared with 81% in the Siegal study, which could explain some of the difference. PRES following allogeneic HCT has often been associated with CNI toxicity. 4, 24, 26 Our incidence of PRES is similar to that reported by Wong et al. 24 for patients receiving tacrolimus-based GvHD prevention after allogeneic HCT, 1.6%. However, of interest, only 3 of the 5 patients in our study were receiving a CNI. The other 2 patients were receiving sirolimus and mycophenolate mofetil. Although not common, there have been case reports of PRES associated with sirolimus. 65, 66 Our approach to managing PRES has been to lower the blood pressure and reduce the dose of CNI or change to another immunosuppressive regimen when CNI toxicity is thought to be contributory.
We were not able to identify any modifiable risk factors for CNSCs. We found age at transplant, aGvHD grade III-IV, transfusion-dependent thrombocytopenia and delayed platelet engraftment to be the only significant risk factors for development of CNSCs. The precise mechanism by which severe aGvHD and delayed platelet engraftment lead to increased risk of CNSC is not clear, but could reflect the complicated post-transplant course, prolonged hospitalization and general deconditioning of these patients. Our finding of aGvHD as a risk factor is consistent with a prospective adult study by Sostak et al. 39 and a pediatric study by Uckan et al.;
41 however, we only found an association with grade III-IV aGvHD, and not grade II-IV. Transfusion-dependent . PFS and OS were calculated using Kaplan-Meier estimators. NRM was calculated by accounting for the competing risk of relapse or progression. P-values for curve comparison were calculated using the log-rank test.
thrombocytopenia was associated with many types of CNSC, not only CNS hemorrhage as expected, and this risk factor of thrombocytopenia has not previously been reported. A possible area for future investigation would be the role of platelet alloimmunization in these patients. These data were not available for our patient cohort. Notably, we found no evidence for higher risk of CNSC depending on primary diagnosis, conditioning regimen, donor source or GvHD prophylaxis. We did not replicate the finding of Kishi et al. 40 of use of umbilical cord blood as a risk factor for early NC in the reduced-intensity setting. Furthermore, 17 patients had experienced 21 CNS events before transplant (CNS infection, n = 2; intracranial hemorrhage, n = 4; ischemic stroke, n = 6; seizure, n = 2; CNS disease, n = 6; and PRES, n = 1), but encouragingly these patients were not found to be at increased risk of CNSC post transplant. Therefore, prior neurologic events (for example, during previous rounds of chemotherapy) should not be considered a reason to forego or delay transplant.
Our study has several limitations. First, our study population is heterogeneous, including all patients undergoing allogeneic HCT for hematological malignancies at a single institution. Although this population is likely representative of many major referral centers, the applicability of the results may be limited when considering specific subpopulations of patients undergoing HCT. Furthermore, with 263 patients, our study may not have had sufficient power to detect small effects of some of the covariates that had previously been reported to be risk factors for NC, for example conditioning regimen and TBI.
In summary, NCs, in particular those involving the CNS, remain a significant source of morbidity and mortality following HCT in the modern era. NCs are most common in the early post-transplant period. Age at transplant, the development of aGvHD grades III-IV, transfusion-dependent thrombocytopenia and delayed platelet engraftment are all risk factors. CNSC adversely impacts PFS and OS, and NRM. Strategies to reduce the risk of CNSC might focus on supportive care through the period of thrombocytopenia, as well 
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Abbreviations: ATG = anti-thymocyte globulin; CI = confidence interval; CNS = central nervous system; CSA = cyclosporine A; HL = Hodgkin lymphoma; HR = hazard ratio; MAC = myeloablative conditioning; MMF = mycophenolate mofetil; MRD = matched related donor; MTX = methotrexate; MUD = matched unrelated donor; NHL = non-Hodgkin lymphoma; NRM = non-relapse mortality; OS = overall survival; RIC = reduced-intensity conditioning; SIR = sirolimus; TAC = tacrolimus; UCB = umbilical cord blood donor. Bold indicates results statistically significant at Po 0.05.
as improving prophylaxis regimens to reduce the risk of severe aGvHD.
